3 hours ago
ImmunityBio (IBRX) Shares Plunge 21% Following FDA Warning Letter on Misleading Cancer Drug Marketing
ImmunityBio (IBRX) stock plummeted 21% after the FDA issued a warning letter citing false advertising claims about its bladder cancer drug ANKTIVA.
The post ImmunityBio (IBRX) Shares Plunge 21% Following FDA Warning Letter on Misleading Cancer Drug Marketing appeared first on Blockonomi.
Source: Blockonomi →Related News
- 1 hour ago
CRCL Stock Drops 18% as USDC Activity Jumps 600%
- 2 hours ago
Circle Internet Group (CRCL) Stock Plunges 15.64% as USDC Enters African Markets
- 2 hours ago
Abbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) Takeover
- 2 hours ago
Fundrise Innovation Fund (VCX) Stock Surges Over 740% Amid AI Frenzy
- 2 hours ago
Grab (GRAB) Stock Jumps Nearly 5% on $400M Share Repurchase Plan